-- Orr Inbar, CEO of QuantHealth
Today I get to share something I'm excited about: QuantHealth has raised $45M in Series B funding, led by Qumra Capital and joined by a group of investors who believe, as we do, that drug development doesn't have to be this slow, expensive, or uncertain.
Here's the problem Arnon and I have spent years obsessing over. It takes roughly 10 years to bring a drug to market. Each costs an estimated $3 billion to develop, and about 92% of them fail in clinical trials. Behind each of those failures is a patient who's still waiting for life-changing treatments.
We started QuantHealth because we knew there was a better way – one where biopharma could simulate a trial before it ran, and catch the problems and opportunities on a computer instead of in a patient. This round is about one thing: helping us reach our mission of getting drugs to patients faster, with a lot more confidence along the way.
Why This Moment
A few years ago, "simulation-first clinical development" wasn’t even a topic for discussion. Now it's becoming the standard for the industry thinks. Leaders want to see the evidence before they bet on something new, and I don't blame them- huge amounts of capital and even careers are on the line. But the evidence is starting to speak for itself, and that shift is exactly what makes this such a good time to be doubling down.
I think about where this goes next: a future where in just 5 years, AI will help the industry get 50% more drugs approved per year. That's the scale of the bet we're making, and this funding is what lets us make it.
Why Now
Honestly, the numbers are why. Over the past year, we:
Doubled our clinical trial simulations to more than 600 trials — more than anyone else in the category
Doubled the team with significant expansion into the US
We're also now working with 12 of the top 20 pharma companies globally
None of that is an accident. It's what happens when better predictions -- of who will respond to a therapy, of how patients actually behave in real-world trial settings -- start to compound. Better predictions mean more confidence, less rework, and less risk for everyone involved, especially the patients on the other end of these decisions.
What's Next
Since our Series A, the shift for us has been practical: going from simulating one protocol at a time to exploring thousands of protocol options in the time it used to take to test one. With this new capital, we're investing in:
Core modeling and infrastructure, including our foundation model, our modeling capabilities, and the data that underpins both
Broader product deployment so more pharma teams can put simulation to work in their everyday decisions, not just their biggest bets
An end-to-end clinical development platform that puts simulation directly in the hands of researchers, scientists, operations leaders, and commercial strategists
Our team, we're hiring across commercial, scientific, and medical roles, on both the go-to-market and research-and-delivery sides of the business
If the last few years were about proving this works, the next few are about making it the default way biopharma builds.
Why It's Possible
None of this happens without the people who believed in this before the results made it easy to.
Thank you to Qumra Capital for leading this round, and to our new and existing investors for backing us further. Thank you to our employees, who've put in the work through some genuinely hard years -- and to our mentors and board, whose guidance has shaped nearly every decision along the way.
I'm proud of what this team has built, and even more excited about what's next.